Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Completed 4Terminated 1

Sponsor Class

NIH 6OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Multiple Myeloma 90Neoplasms, Plasma Cell 28Central Nervous System Neoplasms 11Recurrence 10Glioblastoma 10Neoplasms 9Carcinoma, Hepatocellular 9Brain Neoplasms 9Gliosarcoma 8Melanoma 6Lung Neoplasms 6Leukemia 6Glioma 6Carcinoma, Non-Small-Cell Lung 6Waldenstrom Macroglobulinemia 5Prostatic Neoplasms 5Lymphoma, Mantle-Cell 5Myeloproliferative Disorders 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Immunoglobulin Light-chain Amyloidosis 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Astrocytoma 4Uveal Melanoma 3Oligodendroglioma 3Neuroblastoma 3Myelodysplastic-Myeloproliferative Diseases 3Myelodysplastic Syndromes 3Medulloblastoma 3

Interventions

Docetaxel 171Radiotherapy 144Magnetic Resonance Spectroscopy 142Leuprolide 112Prednisone 108enzalutamide 102Radiosurgery 101Abiraterone Acetate 94Androgen Antagonists 91Goserelin 83bicalutamide 81gallium 68 PSMA-11 70Surveys and Questionnaires 63apalutamide 57Specimen Handling 56acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 55Radiation 47Gonadotropin-Releasing Hormone 45Standard of Care 44Biopsy 44Brachytherapy 42Radiotherapy, Intensity-Modulated 40Blood Specimen Collection 40darolutamide 39abiraterone 39cabazitaxel 35Exercise 35Carboplatin 33Pluvicto 32Triptorelin Pamoate 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Prostatic Neoplasms × Thalidomide × Clear all
NCT00038181 2018-11-15

Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
18 enrolled
Genitourinary

Prostatic Neoplasms

NCT00038246 2018-10-31

Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Completed
40 enrolled
Genitourinary

Prostatic Neoplasms

NCT00400517 2018-08-28

GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer

The Cleveland Clinic

Phase 2 Completed
28 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

NCT00307294 2017-11-24

Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)

University of Pittsburgh

Phase 2 Completed
40 enrolled 8 charts
Genitourinary

Prostatic Neoplasms

NCT00450008 2016-03-17

Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer

The Methodist Hospital Research Institute

Phase 2 Terminated
9 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡